Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Oncogenes and Tumor Suppressors

Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions

Bo Wu, Shu Yang, Haimei Sun, Tingyi Sun, Fengqing Ji, Yurong Wang, Lie Xu and Deshan Zhou
Bo Wu
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
2Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing, P. R. China.
3Cancer Institute of Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu Yang
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
2Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing, P. R. China.
3Cancer Institute of Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haimei Sun
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
2Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing, P. R. China.
3Cancer Institute of Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tingyi Sun
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
2Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing, P. R. China.
3Cancer Institute of Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fengqing Ji
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
2Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing, P. R. China.
3Cancer Institute of Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yurong Wang
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lie Xu
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deshan Zhou
1Department of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing, P. R. China.
2Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing, P. R. China.
3Cancer Institute of Capital Medical University, Beijing, P. R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhouds08@ccmu.edu.cn
DOI: 10.1158/1541-7786.MCR-17-0544 Published March 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Low expression of the tumor suppressor Kelch-like ECH-associated protein 1 (KEAP1) in non–small cell lung cancer (NSCLC) often results in higher malignant biological behavior and poor prognosis; however, the underlying mechanism remains unclear. The present study demonstrates that overexpression of Keap1 significantly suppresses migration and invasion of three different lung cancer cells (A549, H460, and H1299). Highly expressed Keap1, compared with the control, promotes formation of multiple stress fibers with larger mature focal adhesion complexes in the cytoplasm where only fine focal adhesions were observed in the membrane under control conditions. RhoA activity significantly increased when Keap1 was overexpressed, whereas Myosin 9b expression was reduced but could be rescued by proteasome inhibition. Noticeably, mouse tumor xenografts with Keap1 overexpression were smaller in size and less metastatic relative to the control group. Taken together, these results demonstrate that Keap1 stabilizes F-actin cytoskeleton structures and inhibits focal adhesion turnover, thereby restraining the migration and invasion of NSCLC. Therefore, increasing Keap1 or targeting its downstream molecules might provide potential therapeutic benefits for the treatment of patients with NSCLC.

Implications: This study provides mechanistic insight on the metastatic process in NSCLC and suggests that Keap1 and its downstream molecules may be valuable drug targets for NSCLC patients. Mol Cancer Res; 16(3); 508–16. ©2018 AACR.

Introduction

Lung cancer is the leading cause of cancer mortality worldwide, due to its steadily increasing incidence, high mortality, and lack of advanced treatment (1, 2). Non–small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers (3, 4) and is difficult to detect in the early stages; thus, most patients are diagnosed in the advanced or metastatic cancer stage. The high mortality rate of NSCLC is largely related to its metastatic behavior (5, 6); therefore, understanding this mechanism is crucial for developing effective treatments for NSCLC in the clinic.

Tumor cell motility is important for its invasion and migration. Cell movement is a sequential series of steps initiated by establishing actin-rich protrusions and stabilizing the leading edge by nascent focal adhesions, followed by F-actin contraction, disassembling focal adhesion at the cell rear, and detaching the tail of the cell, all of which cause forward movement of the cell (7, 8). Previous studies have shown that F-actin reorganization and focal adhesion turnover play key roles in tumor cell invasion and migration (9). RhoA, a member of the Rho-GTPase family, is important for the regulation of actin cytoskeleton dynamics and is involved in many cell biological functions including malignant transformation, cell polarity, and cell migration (10–12). RhoA directly promotes stress fiber formation and focal adhesion maturation, which stabilize the cytoskeleton (13–15). Therefore, alterations of RhoA activity may affect cell motility.

In recent years, a large amount of evidence has suggested that Kelch-like ECH-associated protein 1 (Keap1) often functions as a cancer suppressor (16), as its expression was downregulated in different types of solid cancers including NSCLC (17–19). It was well known that Keap1 proteins have five functional domains: N-terminal (NTR), Bric-a-Brac (BTB) dimerization, intervening or linker region (IVR), double glycine repeat (DGR), and C-terminal region (CTR), of which BTB and DGR are characteristic domains (20). The BTB domain is not only involved in Keap1 homodimerization but also contains the binding site for the cul3-dependent E3 ubiquitin ligase complex (21). Thus, Keap1 may also function as a substrate adaptor protein for the E3 ubiquitin ligase complex to promote protein-ubiquitination degradation through the 26S proteasome (22). The DGR domain is essential for binding to actin proteins, which may play a role for stabilizing the cytoskeleton (23). This is supported by the fact that the majority of Keap1 is often colocalized with F-actin cytoskeleton in the cytoplasm. Based on the molecular and structural characteristics, it is believed that Keap1 may promote F-actin formation and inhibit focal adhesion turnover by enhancing RhoA activity. Furthermore, Keap1 can also stabilize F-actin structures by directly binding to actin proteins. Therefore, the aim of this study is to determine the underlying mechanism of Keap1 inhibition for NSCLC cell invasion and migration, with particular focus on the molecular mechanism of Keap1-mediated actin stabilization and upregulation of RhoA activity. Our results suggest that Keap1 and its downstream molecules may be a valuable drug target for patients with NSCLC.

Materials and Methods

Cell culture

Human NSCLC cell lines NCI-H1299, NCI-H460, and A549 were purchased from ATCC and were cultured for no more than 15 passages. NCI-H1299 and NCI-H460 were cultured in RPMI 1640 (Gibco). While A549 cells were cultured in high-glucose Dulbecco's Modified Eagle's Medium (DMEM). Both mediums were supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 1% penicillin/streptomycin solution (P/S, Gibco). Cell lines were authenticated by short tandem repeat (STR) profiling in 2014 (Shanghai Biowing Applied Biotechnology Co. Ltd). All cell lines used were tested negative for mycoplasma contamination by the PCR mycoplasma detection kit (ABM) in 2015.

Lentiviral-based plasmids transduction

The full-length Keap1 gene was cloned and introduced into the Lentivirus vector (Lentivirus carrying Keap1 (LV-NM_203500) or negative control (LV-CON063) GeneChem). Cells in the logarithmic growth phase were seeded in 3.5 cm dish at a density of 5 × 104 cells/well and infected with LV-NM_203500 or LV-CON063 in 5 μg/mL polybrene when the cells reached 30% confluence. Then cells were selected and evaluated for subsequent experiments.

Real-time monitoring of the cell migration and invasion

Dynamic and real assessments of migration and invasion were performed by measuring the cell index, which is proportional to the number of cells, using the xCELLigence System Real-Time Cell Analysis System (RTCA; ACEA Biosciences; refs. 24, 25). Briefly, the RTCA functions on electronic impedance reading from the gold-plated sensor electrodes that are placed at the bottom of the plats (E-16 plate). Electronic reading change as cells attach the surface electrodes. There is a direct correlation between the number of attaching cells and the value is redout by the RTCA. For migration and invasion, 20,000 cells per well were seeded in the upper chamber or in the 10% matrigel-coated chamber of cell invasion/migration (CIM) plates in serum-free medium. The bottom chambers of the CIM plates were filled with serum-containing medium to promote cell motility and migration. After seeding, the CIM plates were transferred into the RTCA-DP instrument for real-time readouts. Cell motility was assessed at 15-minute intervals for 30 hours. All experiments were repeated four times.

Immunofluorescent staining

Cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.3% TritonX-100 for 20 minutes and then blocked with 1% bovine serum albumin (Sigma-Aldrich) for 1 hour. For focal adhesion staining, the cells were incubated with mouse anti-vinculin antibody (Sigma-Aldrich) at 1:400 overnight at 4°C, followed by Cy3-conjugated secondary antibody (1:300, Invitrogen) for 1 hour at 25°C. Actin filaments were stained using TRITC-Phalloidin (1:250). The cells were mounted by using DAPI mounting medium (Zhongshan Jinqiao Biotech) and observed with a confocal laser scanning microscope with Leica TCS-SP system mounted on a Leica DMI6000 microscope (Leica). Images were collected in 512 × 512 pixel format. The cells were incubated without a primary antibody as negative control.

Immunohistochemistry

Sections (5 μm thick) were made from 4% paraformaldehyde-fixed and paraffin-embedded specimens. The sections were preincubated with pure methanol containing 3% H2O2 to inhibit endogenous peroxidase activity and then incubated in a primary antibody (anti-CK7, 1:400; or anti-ki67, 1:500, Abcam) overnight at 4°C, respectively. The secondary biotinylated goat anti-rabbit IgG was consequently applied. The immunoreactivity was visualized by using streptavidin–peroxidase along with 3, 3′-diaminobenzidine and 0.3% H2O2 as substrate. In control experiments, the primary antibodies were replaced by normal goat serum.

Western blot

Cells were lysed in buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% TritonX-100, 1% sodium deoxycholate, 0.1% SDS, 1 mmol/L PMSF). The protein concentration was determined by NanoDrop 2000c spectrophotometer (Thermo Scientific) using BCA Protein Assay Kit (Applygen Technologies). Whole-cell protein extracts (50 μg) were separated using SDS-PAGE and processed by Western blot analysis using anti- Keap1 (1:20,000, Sigma-Aldrich), vinculin (1:500, Santa Cruz Biotechnology) monoclonal antibodies, β-actin (1:2000, CoWin Biotech) and Myo9b (1:1000, cytoskeleton) polyclonal antibodies at 4°C overnight, followed by incubation with horseradish peroxidase–conjugated secondary antibodies (1:2000, Santa Cruz Biotechnology) for 1 hour. The protein bands were detected by ECL chemiluminescence and analyzed using the Bandscan analysis software (Sterling). A mouse anti-GAPDH (1:2,000, Applygen Technologies) antibody was used as an internal control. The intensity values were analyzed with ImageJ software (NIH).

RhoA G-LISA activation assay

RhoA activation was measured using luminescence-based G-LISA Activation kit (Cytoskeleton Inc.) according to the manufacturer's instructions. Briefly, the infected cells were harvested at 70% confluence and whole cell lysates were extracted. Protein concentrations were measured and balanced to a certain protein concentration between 1 and 2 mg/mL for the assay. Values were normalized by protein content using a colorimetric assay (Bio-Rad Laboratories) according to the manufacturer's recommendations.

Development of the tumor xenograft model

Forty-five male athymic nude mice BALB/c-nu/nu, ages 5 weeks, were purchased from the Laboratory Animal Center of Capital Medical University (Beijing, China). The animal experiments were approved by the Animal Research and Ethical Committee of Capital Medical University. For tumor xenograft establishments, A549 cells overexpressing green fluorescent protein or Keap1 (3 × 106 cells/100 μL) were subcutaneously injected into the right side of the axilla region of mice. Tumor and axillary lymph nodes were collected at 3, 4, 5, and 6 weeks, respectively, after which 5 tumors and 10 lymph nodes from five nude mice were examined each week. In addition, to avoid individual differences in mice, five mice were subcutaneously injected with A549 control cells and Keap1 overexpressing cells into the right and left sides, respectively. The mice were scanned with small animal magnetic resonance imaging (MRI) to observe tumor growth in vivo, and then sacrificed 6 weeks post-injection. Tumor size was measured twice a week using calipers, and was calculated as VT = Length × W2 × π/2.

MRI examination

Small animal MRI was performed with a 7T MR imaging system (PharmaScan70/16US) and surface coil of 35 mm in diameter. Animals were anesthetized using pentobarbital, and then placed in the coil to be scanned. The T2-weighted image sequence was scanned using the following parameters: repetition time/echo time, 2500/35 ms; imaging matrix, 256 × 192; field of view, 20 × 20 mm; slice thickness, 0.7 mm; intersection gap, 0 mm; and number of averages, 6.

Statistical analysis

The data are represented as the means of at least three independent experiments. Statistical analysis was performed using the unpaired Student t test and P value less than 0.05 was considered statistically significant.

Results

Effects of Keap1 on migration and invasion

A549, H460, and H1299 lung cancer cells were transfected by lentivirus with high efficiency infection, and Keap1 expression in the cells was verified by Western blot (Fig. 1A–C). The effects of Keap1 on the migration and invasion of cells were investigated by RTCA. Keap1 overexpression led to a significant reduction in the migration (Fig. 1D and E) and invasion (Fig. 1F and G) of A549 (P < 0.01), H460 (P < 0.01), and H1299 cells (P < 0.01). Serum-free culture medium was used to exclude the effects of proliferation on migration and invasion behaviors. These results demonstrate that the overexpression of Keap1 clearly inhibits the movement of NSCLC cells.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Effects of Keap1 on the migration and invasion of NSCLC cells. A and B, A549 cells were transfected by lentivirus with high efficiency infection, and Keap1 expression in cells was verified by Western blotting (C). Overexpression of Keap1 led to a significant reduction in the migration (D, E) and invasion (F, G) of A549, H460, and H1299 cells (P < 0.01). Right, The average slopes in certain periods of time from three parallel measurements.

Overexpression of Keap1 led to the formation of actin stress fibers in A549 cells

Actin cytoskeleton organization plays key roles in cell movement, and Keap1 is an actin-binding protein but it remains unclear if it can stabilize F-actin and affect cell behavior; therefore, we observed the reorganization of F-actin in different groups. Our results clearly showed that Keap1 was often colocalized with F-actin in the cytoplasm (Fig. 2A). Prominent F-actin bundles and abundant parallel stress fibers throughout the cytoplasm were distinctly seen in the Keap1-overexpressing cells, while control cells only showed lots of punctuated or short rod-like F-actin diffused throughout the cytoplasm (Fig. 2B). One observation field had obviously thicker and relatively stable F-actin stress fibers in Keap1-overexpressing cells compared with the nonexpressing cells (Fig. 2C). These data show that the overexpressed Keap1 in the cells evidently promotes the formation of stress fibers and reduces its reorganization.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Morphology and distribution of the F-actin cytoskeleton in Keap1-overexpressing A549 cells. A, Keap1 was colocalized with F-actin. B, Distribution of F-actin in Keap1-overexpressing cells and GFP control cells. C, In one observation field, thicker and well-aligned F-actin stress fibers could be observed in Keap1-overexpressing cells compared with nonexpressing cells. Green indicates Keap1 marked by GFP. Red indicates F-actin stained with TRITC-Phalloidin. The merged image is the enlarged picture shown in the box. Scale bar, 25 μm (A), 50 μm (B), 10 μm (C).

Keap1 inhibited turnover of the focal adhesion complex

It has been speculated that focal adhesions play a critical role in cell migration. In this study, the alterations of vinculin, a protein associated with cell–cell and cell–matrix junctions, in focal adhesions were detected. Clearly, the number and size of focal adhesions, mainly located in the cytoplasm, were significantly increased in the Keap1-overexpressing cells. In contrast, focal adhesions were tiny and sparsely arranged at the peripheral edge of the control cells (Fig. 3A). Moreover, the vinculin expression was significantly enhanced in the Keap1-overexpressing cells compared with control cells as shown by Western blot (Fig. 3B and C), suggesting that Keap1 not only effects on the maturation and distribution of focal adhesions, but also increases their protein levels. In addition, mature focal adhesion complexes attached to the ends of stress fibers in the Keap1-overexpressing cells, which may also stabilize the F-actin architecture (Fig. 3D). These results support that Keap1 can inhibit focal adhesion turnover, and enhance the formation of stress fibers to play an inhibited role of the cell motility.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Morphology and distribution of focal adhesion in Keap1-overexpressing cells. A, Keap1-induced changes of focal adhesion by vinculin immunostaining. Arrow points out tiny adhesion plaques along the plasma membrane of control cells, compared with large focal adhesion complexes dispersed in the cytoplasm of Keap1-overexpressing cells. B, Vinculin was upregulated in Keap1-overexpressing cells compared with wild-type and GFP control cells, as determined by Western blotting. C, Statistical data from three independent experiments are presented. D, Focal adhesion complexes bound the filament ends in Keap1-overexpressing cells. Scale bar, 50 μm.

Effects of Keap1 were mainly Myo9b–RhoA-dependent

RhoA is a key regulator of focal adhesion turnover and actin dynamics. As shown in Fig. 4, RhoA activity was markedly increased in the Keap1-overexpressing cells, but its expression was not obviously changed (Fig. 4A and B). Treating the cells with Y27632 (5 μmol/L, 24 hours), a Rho kinase inhibitor, resulted in actin depolymerization and the presence of very fine actin cables within the cytoplasm (Fig. 4C), which significantly enhanced cell migration (Fig. 4D). These results indicate that the decreased migration in Keap1 overexpression may mainly depend on RhoA activation. Previous studies have reported that class IX myosins (Myo9) are unconventional members of the myosin family in that their tail domain contains a RhoGTPase-activating protein. Of them, Myo9b, one member of the Myo9 family, specifically targets Rho protein and downregulates RhoA activity (26). Western blot showed that Myo9b expression was reduced in Keap1-overexpressing cells compared with the control. The decrease of Myo9b expression could be rescued by treatment with MG132 (2 μmol/L, 24 hours), a proteasome inhibitor (Fig. 5A). F-actin stress fibers in Keap1 overexpressing cells were reorganized to form actin network beneath the cell membrane after treatment with MG132 (Fig. 5B). These results indicate that Keap1 obviously enhances RhoA activity by promoting the ubiquitination-mediated proteasomal degradation of Myo9b.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Regulation of Keap1-dependent cell migration via a RhoA/ROCK-dependent mechanism. A and B, RhoA activity was markedly increased in Keap1-overexpressing cells, but its expression was not obviously changed. C, F-actin stress fibers were disrupted upon treatment with the inhibitor Y47632. D, Cell motility was rescued significantly after treatment with the Rho kinase inhibitorY27632 by RCTA. Data from three parallel experiments were used for statistical analyses. Scale bar, 50 μm.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Involvement of Myo9b in the regulation of Keap1 on F-actin reorganization. A, Expression of Myo9b was reduced in Keap1-overexpressing cells, which could be rescued by treatment with the MG132 proteasome inhibitor. B, F-actin was reorganized, becoming fewer and thinner and forming cortical fibers under the plasma membrane after MG132 treatment. Scale bar, 20 μm.

Tumor xenograft experiments

To examine the effects of Keap1 overexpression on tumor growth and metastasis in vivo, the mice with tumor xenografts were regularly checked for any sign of poor general health and stayed healthy until sacrifice. Tumor size was measured with calipers and the results are shown in Fig. 6. Keap1 overexpression cells clearly inhibited tumor growth and reduced the expression of Ki67, a proliferation marker (27), compared with the control group (Fig. 6A and B). MRI results also showed significant invasion and the rapid growth of tumors in the control group compared with Keap1-overexpressing tumors (Fig. 6C). Importantly, the tumor cells metastasis into lymph nodes was often observed (Fig. 6D), and occurred much earlier in control A549 tumors than in A549-Keap1 tumors (Table 1). Although these results might not be sufficient for evaluating tumor metastasis, it still reflects the motility of tumor cells in a certain extent.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Effects of Keap1 supression on the growth and metastasis of xenograft tumors. A, Tumor volume was measured every 2 days. Overexpressed Keap1 clearly inhibited tumor growth in vivo. B, Ki67 expression was significantly reduced in Keap1-overexpressing tumors compared with the control group. C, Subcutaneous edema, which might signify inflammatory infiltration, and a large area of necrosis were observed in the control group in T2-weighted magnetic resonance images, which were not prominent in the Keap1 group. The red arrow indicates necrosis, and the yellow arrow indicates inflammatory infiltration. D, Tumor cells were observed in lymph nodes by CK7 staining. Scale bar, 20 μm.

View this table:
  • View inline
  • View popup
Table 1.

Lymph node metastasis in mouse models

Discussion

Keap1 is considered to be a tumor suppressor due to its ability to inhibit tumor progression (28). However, in the past years, Keap1 studies have mainly focused on antioxidative stress through the Keap1/Nrf2/ARE signaling pathway (29–31). It was reported that high methylation of CpG islands in the Keap1 promoter significantly downregulated its expression in NSCLC tissues and cells (32). Moreover, reducing Keap1 expression promoted breast cancer metastasis (33, 34). However, the mechanism underlying Keap1 inhibition of tumor metastasis and its effects on cell behaviors have remained unclear. In the present study, we demonstrated that overexpression of Keap1 not only promoted stress fiber formation but also inhibited focal adhesion turnover, in which the tumor cells exhibited prominent stress fibers and many large mature focal adhesions. The invasion and motility of NSCLC cells were significantly inhibited after Keap1 overexpression, which indicated that the Keap1 played vital roles in inhibiting NSCLC metastasis.

F-actin reorganization and focal adhesion turnover frequently play key roles in cell motility. Our study clearly saw the prominent dense stress fiber bundles distributed in parallel arrays throughout the cytoplasm of the Keap1 overexpression cells. Accordingly, cells enriched with stress fibers often showing slower movement in breast cancer cells (34, 35), which was also observed in our study, as cell motility was reduced when the F-actin cytoskeleton failed to reorganize or stabilize as stress fiber bundles. Furthermore, constant focal adhesion turnover was observed in the control cells; small new nascent adhesions formed at the leading edge, matured into focal adhesions, and then disassembling at the cell rear allowing for cell detachment. Generally, nascent adhesions are much smaller but transmit stronger forces than focal adhesions. Rapidly migrating cells constantly have many smaller adhesion clusters, whereas cells with large focal adhesions are typically either nonmigratory or move very slowly (36). In the current study, many larger mature focal adhesions were seen in the Keap1 overexpression cells than in the control, supporting that the Keap1 could inhibit the turnover of focal adhesions.

Regarding the mechanism of increased stress fiber bundles and mature focal adhesions in Keap1 overexpression cells, our results indicated that activity of the RhoA was clearly upregulated. Previous studies have reported that F-actin cytoskeleton reorganization and focal adhesion turnover are mediated by Rho GTPases signaling, which is a critical mechanism of cell migration during cancer metastasis (37). In this study, RhoA activity was significantly enhanced in the Keap1 overexpression cells compared with the control. Furthermore, migration deficiency in Keap1 overexpression cells could be partly rescued by treatment with the Rho-kinase inhibitor Y-27632. These results indicate that RhoA activity is important for inducing the stability of actin-stress fibers, which might contribute to the Keap1-mediated inhibition of cell migration.

It has been considered that myosinIXb (Myo9b), a Rho GTPase-activating protein, is essential for the negative regulation of Rho activity (38, 39). Keap1 acts as a substrate adaptor protein for the cullin 3-containing E3-ligase, which can degrade ubiquitinated proteins such as Nrf2. It is reported that Myo9b is highly expressed in lung cancer in which Keap1 is often downregulated (40). Because Keap1 colocalizes with F-actin where myo9b also bound. We therefore hypothesized that Keap1 might interact with Myo9b to ubiquitinate and degrade Myo9b, thereby upregulating RhoA activity. Actually, the present study demonstrated that Myo9b expression was clearly reduced in Keap1 overexpression cells and rescued after treatment with the MG132 proteasome inhibitor. Thus, it is reasonable to believe that Keap1 downregulate expression ofMyo9b protein and then, upregulate RhoA activity, thereby contributing to inhibition of the invasion and migration in NSCLC cells. This phenomenon was also observed in vivo where Keap1 inhibited lymph node metastasis in tumor xenografts. Additionally, Keap1 protein has five functional domains and its DGR domain often binds with actin proteins. This conformation not only explains the frequently observed colocalization of Keap1 with F-actin but also help to understand the role of Keap1 in directly stabilizing F-actin stress fibers and restraining the motility of NSCLC cells.

In conclusion, the present results indicate that Keap1 may stabilize the cytoskeleton by both directly binding to F-actin or by indirectly upregulating RhoA activity through decreasing expression of Myo9b protein, thereby inhibiting F-actin remodeling and focal adhesion turnover. Therefore, we propose that Keap1 may be a critical suppressor of metastatic progression of NSCLC, and increasing Keap1 or targeting its downstream molecules might provide potential therapeutic benefits for the treatment of patients with NSCLC.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: B. Wu, D. Zhou

Development of methodology: B. Wu, H. Sun, T. Sun

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Yang, H. Sun, T. Sun, Y. Wang, L. Xu

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Wu, S. Yang, Y. Wang, L. Xu, D. Zhou

Writing, review, and/or revision of the manuscript: B. Wu, D. Zhou

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Sun, T. Sun, F. Ji

Study supervision: B. Wu, F. Ji

Acknowledgments

This work was funded by the National Science Foundation of China (81101769, 81300285 and 31771332), Beijing Natural Science Foundation (7172021 and 5172008), Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan (IDHT20170516), and Science Foundation of Capital Medical University [17ZR09].

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received October 10, 2017.
  • Revision received November 12, 2017.
  • Accepted December 7, 2017.
  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Schabath MB,
    2. Cress D,
    3. Munoz-Antonia T
    . Racial and ethnic differences in the epidemiology and genomics of lung cancer. Cancer Control 2016;23:338–46.
    OpenUrl
  2. 2.↵
    1. Walker S
    . Updates in non-small cell lung cancer. Clin J Oncol Nurs 2008;12:587–96.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Reckamp KL
    . Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Lett 2012;321:101–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Schiffmann I,
    2. Greve G,
    3. Jung M,
    4. Lübbert M
    . Epigenetic therapy approaches in non-small cell lung cancer: update and perspectives. Epigenetics 2016;11:858–70.
    OpenUrl
  5. 5.↵
    1. Yang P
    . Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009;471:469–86.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Shih JY,
    2. Yang PC
    . The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011;32:1299–304.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Xu Y,
    2. Bismar TA,
    3. Su J,
    4. Xu B,
    5. Kristiansen G,
    6. Varga Z,
    7. et al.
    Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med 2010;207:2421–37.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Flaherty B,
    2. McGarry JP,
    3. McHugh PE
    . Mathematical models of cell motility. Cell Biochem Biophys 2007;49:14–28.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Verma D,
    2. Meng F,
    3. Sachs F,
    4. Hua SZ
    . Flow-induced focal adhesion remodeling mediated by local cytoskeletal stresses and reorganization. Cell Adh Migr 2015;9:432–40.
    OpenUrl
  10. 10.↵
    1. Chen Y,
    2. Yang Z,
    3. Meng M,
    4. Zhao Y,
    5. Dong N,
    6. Yan H,
    7. et al.
    Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell 2009;35:841–55.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hu T,
    2. Guo H,
    3. Wang W,
    4. Yu S,
    5. Han L,
    6. Jiang L,
    7. et al.
    Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma. Oncol Rep 2013;30:1707–14.
    OpenUrl
  12. 12.↵
    1. Amano M,
    2. Nakayama M,
    3. Kaibuchi K
    . Rho-Kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton 2010;67:545–54.
    OpenUrl
  13. 13.↵
    1. Steffen A,
    2. Stradal TE,
    3. Rottner K
    . Signalling pathways controlling cellular actin organization. Handb Exp Pharmacol 2017;235:153–78.
    OpenUrl
  14. 14.↵
    1. Aguilar-Rojas A,
    2. Huerta-Reyes M,
    3. Maya-Núñez G,
    4. Arechavaleta-Velásco F,
    5. Conn PM,
    6. Ulloa-Aguirre A,
    7. et al.
    Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231. BMC Cancer 2012;12:550.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Tojkander S,
    2. Gateva G,
    3. Lappalainen P
    . Actin stress fibers-assembly, dynamics and biological roles. J Cell Sci 2012;125:1855–64.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Sasaki H,
    2. Suzuki A,
    3. Shitara M,
    4. Okuda K,
    5. Hikosaka Y,
    6. Moriyama S,
    7. et al.
    Keap1 mutations in lung cancer patients. Oncol Lett 2013;6:719–21.
    OpenUrlPubMed
  17. 17.↵
    1. Wang R,
    2. An J,
    3. Ji F,
    4. Jiao H,
    5. Sun HM,
    6. Zhou DS
    . Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008;373:151–4.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hayes AJ,
    2. Skouras C,
    3. Haugk B,
    4. Charnley RM
    . Keap1-Nrf2 signalling in pancreatic cancer. Int J Biochem Cell Biol 2015;65:288–99.
    OpenUrl
  19. 19.↵
    1. Zhang L,
    2. Yang WP,
    3. Wu LY,
    4. Zhu X,
    5. Wei CY
    . Expression and clinical significance of Kelch-like epichlorohydrin-associated protein 1 in breast cancer. Genet Mol Res 2016;15:gmr.15027294.
  20. 20.↵
    1. Cleasby A,
    2. Yon J,
    3. Day PJ,
    4. Richardson C,
    5. Tickle IJ,
    6. Williams PA,
    7. et al.
    Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS One 2014;9:e98896.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Mulvaney KM,
    2. Matson JP,
    3. Siesser PF,
    4. Tamir TY,
    5. Goldfarb D,
    6. Jacobs TM,
    7. et al.
    Identification and characterization of MCM3 as a Kelch-like ECH-associated protein 1 (KEAP1) substrate. J Biol Chem 2016;291:23719–33.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Zipper LM,
    2. Mulcahy RT
    . The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 2002;277:36544–52.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Ito A,
    2. Shimazu T,
    3. Maeda S,
    4. Shah AA,
    5. Tsunoda T,
    6. Iemura S,
    7. et al.
    The subcellular localization and activity of cortactin is regulated by acetylation and interaction with Keap1. Sci Signal 2015;8:ra120.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Tan J,
    2. Yang S,
    3. Shen P,
    4. Sun H,
    5. Xiao J,
    6. Wang Y,
    7. et al.
    C-kit signaling promotes proliferation and invasion of colorectal mucinous adenocarcinoma in a murine model. Oncotarget 2015;6:27037–48.
    OpenUrl
  25. 25.↵
    1. Moniri MR,
    2. Young A,
    3. Reinheimer K,
    4. Rayat J,
    5. Dai LJ,
    6. Warnock GL
    . Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology 2015;67:379–86.
    OpenUrl
  26. 26.↵
    1. Hanley PJ,
    2. Xu Y,
    3. Kronlage M,
    4. Grobe K,
    5. Schön P,
    6. Song J,
    7. et al.
    Motorized RhoGAP myosin IXb (Myo9b) controls cell shape and motility. Proc Natl Acad Sci 2010;107:12145–150.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Kim H,
    2. Park CY,
    3. Lee JH,
    4. Kim JC,
    5. Cho CK,
    6. Kim HJ
    . Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. Ann Surg Treat Res 2015;88:200–7.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Nordgren KK,
    2. Wallace KB
    . Keap1 redox-dependent regulation of doxorubicin-induced oxidative stress response in cardiac myoblasts. Toxicol Appl Pharmacol 2014;274:107–16.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Iso T,
    2. Suzuki T,
    3. Baird L,
    4. Yamamoto M
    . Absolute amounts and status of Nrf2-Keap1-Cul3 complex within cells. Mol Cell Biol 2016;36:3100–12.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Chechushkov A,
    2. Zaitseva N,
    3. Vorontsova E,
    4. Kozhin P,
    5. Menshchikova E,
    6. Shkurupiy V
    . Dextran loading protects macrophages from lipid peroxidation and induces a Keap1/Nrf2/ARE-dependent antioxidant response. Life Sci 2016;166:100–7.
    OpenUrl
  31. 31.↵
    1. Deny LJ,
    2. Traboulsi H,
    3. Cantin AM,
    4. Marsault E,
    5. Richter MV,
    6. Bélanger G
    . Bis-michael acceptors as novel probes to study the Keap1/Nrf2/ARE pathway. J Med Chem 2016;59:9431–42.
    OpenUrl
  32. 32.↵
    1. Guo D,
    2. Wu B,
    3. Yan J,
    4. Li X,
    5. Sun H,
    6. Zhou D
    . A possible gene silencing mechanism: hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells. Biochem Biophys Res Commun 2012;428:80–5.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Kim MS,
    2. Lee WS,
    3. Jin W
    . TrkB promotes breast cancer metastasis via suppression of Runx3 and Keap1 expression. Mol Cells 2016;39:258–65.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Wilson AL,
    2. Schrecengost RS,
    3. Guerrero MS,
    4. Thomas KS,
    5. Bouton AH
    . Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. PLoS One 2013;8:e65678.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Schrecengost RS,
    2. Riggins RB,
    3. Thomas KS,
    4. Guerrero MS,
    5. Bouton AH
    . Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res 2007;67:6174–82.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Shan Y,
    2. Yu L,
    3. Li Y,
    4. Pan Y,
    5. Zhang Q,
    6. Wang F,
    7. et al.
    Nudel and FAK as antagonizing strength modulators of nascent adhesions through paxillin. PLoS Biol 2009;7:e1000116.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Ridley AJ
    . Rho GTPase signalling in cell migration. Curr Opin Cell Biol 2015;36:103–12.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. McMichael BK,
    2. Scherer KF,
    3. Franklin NC,
    4. Lee BS
    . The RhoGAP activity of myosin IXB is critical for osteoclast podosome patterning, motility, and resorptive capacity. PLoS One 2014;9:e87402.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Xu Y,
    2. Pektor S,
    3. Balkow S,
    4. Hemkemeyer SA,
    5. Liu Z,
    6. Grobe K,
    7. et al.
    Dendritic cell motility and T cell activation requires regulation of Rho-cofilin signaling by the Rho-GTPase activating protein myosin IXb. J Immunol 2014;192:3559–68.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Kong R,
    2. Yi F,
    3. Wen P,
    4. Liu J,
    5. Chen X,
    6. Ren J,
    7. et al.
    Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression. J Clin Invest 2015;125:4407–20.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Molecular Cancer Research: 16 (3)
March 2018
Volume 16, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions
Bo Wu, Shu Yang, Haimei Sun, Tingyi Sun, Fengqing Ji, Yurong Wang, Lie Xu and Deshan Zhou
Mol Cancer Res March 1 2018 (16) (3) 508-516; DOI: 10.1158/1541-7786.MCR-17-0544

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions
Bo Wu, Shu Yang, Haimei Sun, Tingyi Sun, Fengqing Ji, Yurong Wang, Lie Xu and Deshan Zhou
Mol Cancer Res March 1 2018 (16) (3) 508-516; DOI: 10.1158/1541-7786.MCR-17-0544
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Driver Genes Identified in DLBCL Using an SB Screen
  • CCR2 Modulation of Tumor Cell Growth
  • STRAP Supports HCC Cell Growth
Show more Oncogenes and Tumor Suppressors
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement